WallStreetZenWallStreetZen

NASDAQ: PRPH
Prophase Labs Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their PRPH stock forecasts and price targets.

Forecast return on equity

Is PRPH forecast to generate an efficient return?
Company
N/A
Industry
25.1%
Market
48.93%

Forecast return on assets

Is PRPH forecast to generate an efficient return on assets?
Company
N/A
Industry
11.13%

PRPH earnings per share forecast

What is PRPH's earnings per share in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$1.23
Avg 2 year Forecast
-$0.80

PRPH revenue forecast

What is PRPH's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$14.8M-17.67%
Avg 2 year Forecast
$50.2M+179.56%
Avg 3 year Forecast
$95.0M+428.87%
PRPH's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PRPH revenue growth forecast

How is PRPH forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
73.27%
Industry
6.85%
Market
9.84%
PRPH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PRPH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PRPH vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
PRPH$2.41N/AN/A
XGN$2.65$7.00+164.15%Strong Buy
NOTV$1.84$5.92+221.58%Buy
OCX$3.05$4.42+44.82%Buy
PRE$4.29N/AN/A
View Top Diagnostic & Research Stocks

Prophase Labs Stock Forecast FAQ

What is PRPH's earnings growth forecast for 2024-2025?

(NASDAQ: PRPH) Prophase Labs's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 18.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.87%.

Prophase Labs's earnings in 2024 is -$26,310,000.On average, 1 Wall Street analyst forecast PRPH's earnings for 2024 to be -$23,466,591, with the lowest PRPH earnings forecast at -$23,466,591, and the highest PRPH earnings forecast at -$23,466,591.

In 2025, PRPH is forecast to generate -$15,262,823 in earnings, with the lowest earnings forecast at -$15,262,823 and the highest earnings forecast at -$15,262,823.

If you're new to stock investing, here's how to buy Prophase Labs stock.

What is PRPH's revenue growth forecast for 2024-2026?

(NASDAQ: PRPH) Prophase Labs's forecast annual revenue growth rate of 73.27% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 6.85%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.84%.

Prophase Labs's revenue in 2024 is $17,972,000.On average, 1 Wall Street analysts forecast PRPH's revenue for 2024 to be $282,285,915, with the lowest PRPH revenue forecast at $282,285,915, and the highest PRPH revenue forecast at $282,285,915. On average, 1 Wall Street analysts forecast PRPH's revenue for 2025 to be $958,562,533, with the lowest PRPH revenue forecast at $958,562,533, and the highest PRPH revenue forecast at $958,562,533.

In 2026, PRPH is forecast to generate $1,813,376,024 in revenue, with the lowest revenue forecast at $1,813,376,024 and the highest revenue forecast at $1,813,376,024.

What is PRPH's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: PRPH) forecast ROA is N/A, which is lower than the forecast US Diagnostics & Research industry average of 11.13%.

What is PRPH's Earnings Per Share (EPS) forecast for 2024-2025?

(NASDAQ: PRPH) Prophase Labs's current Earnings Per Share (EPS) is -$1.49. On average, analysts forecast that PRPH's EPS will be -$1.23 for 2024, with the lowest EPS forecast at -$1.23, and the highest EPS forecast at -$1.23. In 2025, PRPH's EPS is forecast to hit -$0.80 (min: -$0.80, max: -$0.80).

What is PRPH's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: PRPH) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.